SCHEDULE 13G/A: Novartis Entities Reaffirm 5.4% Passive Stake in Precision Biosciences

Novartis Pharma AG and its parent company Novartis AG have filed an amended Schedule 13G, confirming their continued beneficial ownership of 5.4% of Precision Biosciences Inc.'s common stock as of December 31, 2024.

Summary

• Novartis Pharma AG and its publicly-owned parent, Novartis AG, collectively hold 413,581 shares of Precision Biosciences Inc. common stock.
• This ownership represents a 5.4% beneficial stake in Precision Biosciences Inc.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a routine update to a previously disclosed passive investment.
• The ownership percentage is calculated based on 7,671,059 outstanding shares of Precision Biosciences Inc. common stock, as reported in the issuer's Quarterly Report on Form 10-Q filed on November 4, 2024.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Precision Biosciences Inc.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual disclosure of passive ownership and does not contain information that would significantly alter sentiment positively or negatively regarding the issuer's performance or outlook.

Positives

• Novartis, a prominent global pharmaceutical company, maintains a significant passive investment in Precision Biosciences, which could be interpreted as a signal of long-term confidence in the company's prospects or technology.

Negatives

• The document, being a passive ownership disclosure, does not contain any negative information regarding Precision Biosciences Inc.'s operational or financial performance.

Risks

• The document does not explicitly mention any specific risks related to Precision Biosciences Inc.'s operations, financial health, or market position, as its primary purpose is to disclose beneficial ownership.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Precision Biosciences Inc.'s future performance, strategic direction, or financial outlook, as it is a passive ownership disclosure.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a continued passive investment by a major global pharmaceutical company, Novartis, in a biotechnology firm, Precision Biosciences. Such investments are common in the life sciences sector, where larger entities may take strategic stakes in innovative smaller companies without seeking control, potentially for future collaborations or as a long-term portfolio holding.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves to disclose a passive ownership stake and does not provide operational or financial results for comparison. Therefore, specific comparisons to industry benchmarks or competitor performance are not applicable based on the content provided.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive shareholder's stake, confirming Novartis's continued investment in Precision Biosciences Inc.
• Management: Confirms the presence of a major passive shareholder, but without intent to influence control, suggesting no direct impact on operational decision-making.

Next Steps

• The document does not specify any future actions, events, or milestones for Precision Biosciences Inc. or the reporting persons beyond the routine filing requirements.

Key Dates

Keywords

Precision Biosciences Inc., Novartis Pharma AG, Novartis AG, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Biotechnology, Pharmaceutical Investment, Passive Investment